Warfarin Pharmacogenomics: A big step forward for individualized medicine: Enlightened dosing of warfarin

European Journal of Human Genetics

Volumn 16, Issue 5, 2008, Pages 532-534

  Elias, Darlene J ^a   Topol, Eric J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C9; OXIDOREDUCTASE; WARFARIN;

BLEEDING; CEREBROVASCULAR ACCIDENT; CIGARETTE SMOKING; COST EFFECTIVENESS ANALYSIS; DNA POLYMORPHISM; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; FOOD; FOOD DRUG INTERACTION; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIVER DISEASE; LOW DRUG DOSE; NOTE; OPTIMAL DRUG DOSE; PHARMACOGENETICS; PRESCRIPTION; PRIORITY JOURNAL; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; DRUG MONITORING; GENOTYPE; HUMANS; PHARMACOGENETICS; PRESCRIPTIONS, DRUG; WARFARIN;

EID: 42649095148     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/sj.ejhg.5201945     Document Type: Note

References (9)

1. Ansell J, Hirsh J, Poller L et al: The pharmacology and management of the vitamin K antagonists: The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004; 126: 204-233.
2. Rieder MJ, Reiner AP, Gage BF et al: Effect of VKORC1 Haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352: 2285-2293.
3. Kamali F, Khan TI, King BP et al: Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clin Pharmacol Ther 2004; 75: 204-212.
4. Carlquist JF, Horne BD, Muhlestein JB: Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase comlex subunit 1 conjointly determine stable warfarin dose: A prospective study. J Thromb Thrombolysis 2006; 22: 191-197.
5. Wadelius M, Chen LY, Eriksson N et al: Association of warfarin dose with genes involved in its action and metabolism. Hum Genet 2007; 121: 23-34.
6. Higashi MK, Veenstra DL, Kondo LM et al: Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002; 287: 1690-1698.
7. Millican EA, Lenzini PA, Miligan PE et al: Genetic-based dosing in orthopedic patients beginning warfarin therapy. Blood 2007; 110 1511-1515.
8. Matthews A: In Milestone, FDA pushes genetic tests tied to drug. Wall St J, August 16, 2007.
9. Witt DM, Sadler MA, Shanahan RL, et al: Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy. Chest 2005; 127: 1515-1522.